stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Revenue growth
CRISPR Therapeutics AG's revenue growth over the twelve months to 30 September 2026 was −34.3%, up 56.2 percentage points from fiscal 2025 (−90.6%). Over the past ten years it has ranged from −99.9% (fiscal 2022) to 127,154.9% (fiscal 2021); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of 6.76% and below the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −90.6% | (0.64) |
| FY2024 | −90.0% | (30,975.43) |
| FY2023 | 30,885.5% | 30,985.35 |
| FY2022 | −99.9% | (127,254.81) |
| FY2021 | 127,154.9% | 127,254.69 |
| FY2020 | −99.8% | (9,269.60) |
| FY2019 | 9,169.9% | 9,262.23 |
| FY2018 | −92.4% | (786.28) |
| FY2017 | 693.9% | (1,296.79) |
| FY2016 | 1,990.7% | 2,085.91 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 1,325.1% | 283.71 |
| Jun 2026 | 1,041.4% | 972.82 |
| Mar 2026 | 68.6% | 166.13 |
| Dec 2025 | −97.6% | (145.25) |
| 38 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 59.6% |
| TVTX Travere Therapeutics, Inc. compare | 49.4% |
| DNTH Dianthus Therapeutics, Inc. compare | −11.7% |
| CRSP CRISPR Therapeutics AG | −34.3% |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement